The Lenexa-based company (Nasdaq: MEDW) announced the definitive merger agreement with Thoma Bravo LLC on Wednesday. Mediware shareholders, who still must approve the deal, stand to get $22 a share in cash.

The company makes software and other technology designed to help hospitals and other health care providers with billing and performance management, as well as to better manage their blood products, medication, and stem cell and cancer treatment therapies. Much of its growth during the past year has been tied to contracts assisting the Department of Defense with global blood supplies management.

Mediware finished its 2012 fiscal year in June with net income of $7.5 million on $64.6 million in revenue, compared with profits of $6.3 million on $55.5 million in revenue the prior year.

“Mediware has sustained consistent revenue and earnings growth over the past five years by focusing on effectively expanding its product portfolios to new areas of care,” Mediware President and CEO Thomas Mann said in a written statement. “The acquisition by Thoma Bravo recognizes this performance and validates our belief that Mediware is positioned for continued growth and profitability in the future.”

The company plans to continue investing in its products and people, he said. At the end of June, Mediware had 306 employees, with all but 39 working in the United States.

“We see strong growth potential as more and more organizations seek technology solutions to improve the management of their clinical, regulatory and financial operations,” Thoma Bravo Managing Partner Scott Crabill said in a written statement, noting Mediware’s good reputation.

The deal is subject to customary closing conditions, including regulatory and shareholder approvals. It is expected to close by the end of the year, giving Thoma Bravo 100 percent ownership of Mediware’s outstanding shares.

Thoma Bravo, whose website lists offices in Chicago and San Francisco, manages several private equity funds representing almost $4 billion of equity commitments. The firm focuses on investments in companies involved with business services, education, financial services and software/technology. It appears that Mediware would be its second health care-related investment, following occupational training firm Porter & Chester Institute Inc.